Business Context and Reporting Period
DarioHealth Corp. (DRIO), an emerging growth company incorporated in Delaware, filed this Form 8-K on May 22, 2019. The report details the entry into a material definitive agreement for a firm commitment underwritten public offering.
Key Financial Metrics and Offering Details
- Offering Structure: Sale of 4,855,341 shares of common stock and pre-funded warrants to purchase 7,175,525 shares of common stock.
- Public Offering Price: $0.60 per share for common stock; $0.5999 per pre-funded warrant.
- Estimated Net Proceeds: Approximately $6.5 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Expected Closing Date: May 24, 2019, subject to customary closing conditions.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Terms
The primary material change is the execution of an underwriting agreement with Craig-Hallum Capital Group LLC. The offering is being made pursuant to a shelf registration statement on Form S-3 filed in 2016. The pre-funded warrants are exercisable at any time after issuance but are subject to beneficial ownership limitations (4.99% or 9.99% at the purchaser's election, and a 19.99% cap unless shareholder approval is obtained).
Guidance, Outlook, and Risks
Management expects the offering to close on May 24, 2019. The filing includes standard representations and warranties, market standoff provisions, and indemnification obligations. The document explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy in jurisdictions where such actions would be unlawful prior to registration. No specific operational guidance or risk factors beyond standard securities law disclosures are detailed in this specific text.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected May 24, 2019) and the final net proceeds received.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Confirm the exercise terms and beneficial ownership limitations of the pre-funded warrants (Exhibit 4.1).
- Check subsequent filings for the impact of this capital raise on the company's cash position and dilution to existing shareholders.